Ayelet Chajut
Nessuna posizione attualmente
Profilo
Ayelet Chajut worked as Vice President-Research at Pluri, Inc., Vice President-Research at Quark Pharmaceuticals, Inc., and Executive Vice President-Research & Development at Rosetta Genomics Ltd.
She holds a doctorate degree from Tel-Aviv University.
Precedenti posizioni note di Ayelet Chajut
| Società | Posizione | Fine |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Direttore Tecnico/Scientifico/R&S | - |
| PLURI INC. | Direttore Tecnico/Scientifico/R&S | - |
| ROSETTA GENOMICS LTD. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Ayelet Chajut
| Tel-Aviv University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ROSETTA GENOMICS LTD. | Health Technology |
| PLURI INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Borsa valori
- Insiders
- Ayelet Chajut
